Detalhe da pesquisa
1.
CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Clin Epigenetics
; 15(1): 112, 2023 07 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37415208
2.
SAIL--a software system for sample and phenotype availability across biobanks and cohorts.
Bioinformatics
; 27(4): 589-91, 2011 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21169373
3.
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma.
Clin Epigenetics
; 11(1): 161, 2019 11 20.
Artigo
Inglês
| MEDLINE | ID: mdl-31747929
4.
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
EBioMedicine
; 48: 341-352, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-31628024
5.
CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.
JCI Insight
; 3(13)2018 07 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29997292
6.
Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.
PLoS One
; 13(2): e0192742, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-29425237
7.
Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
PLoS One
; 12(6): e0179412, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28617833
8.
PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.
Oncotarget
; 8(25): 41011-41020, 2017 Jun 20.
Artigo
Inglês
| MEDLINE | ID: mdl-28487502
9.
Harmonising and linking biomedical and clinical data across disparate data archives to enable integrative cross-biobank research.
Eur J Hum Genet
; 24(4): 521-8, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26306643